IXC 1.52% 6.7¢ invex therapeutics ltd

Ann: Initial FDA and EMA Advice on Presendin Development, page-140

  1. 387 Posts.
    lightbulb Created with Sketch. 47
    I disagree. I think it's just market sentiment and impatience. The fact is that even if the FDA comes back and tells IXC that they need to do 2 trials, it's not catastrophic. They still have an outstanding drug, excellent data, and plenty of cash in the bank. They're still a very suitable takeover target. This is the end game
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.